Effect of Pritelivir Compared With Valacyclovir on Genital HSV-2 Shedding in Patients With Frequent Recurrences | Zendy

Anna Wald | Zendy; Burkhard Timmler | Zendy; Amalia Magaret | Zendy; Terri Warren | Zendy; Stephen K. Tyring | Zendy; Christine Johnston | Zendy; Kenneth H. Fife | Zendy; Stacy Selke | Zendy; MeeiLi Huang | Zendy; Hans-Peter Stobernack | Zendy; Holger Zimmermann | Zendy; Lawrence Corey | Zendy; Alexander Birkmann | Zendy; Helga RuebsamenSchaeff | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Effect of Pritelivir Compared With Valacyclovir on Genital HSV-2 Shedding in Patients With Frequent Recurrences

Author(s) -

Anna Wald,

Burkhard Timmler,

Amalia Magaret,

Terri Warren,

Stephen K. Tyring,

Christine Johnston,

Kenneth H. Fife,

Stacy Selke,

MeeiLi Huang,

Hans-Peter Stobernack,

Holger Zimmermann,

Lawrence Corey,

Alexander Birkmann,

Helga RuebsamenSchaeff

Publication year - 2016

Publication title -

jama

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 4.688

H-Index - 680

eISSN - 1538-3598

pISSN - 0098-7484

DOI - 10.1001/jama.2016.18189

Subject(s) - medicine , viral shedding , sex organ , herpes simplex virus , randomized controlled trial , valaciclovir , herpes genitalis , clinical trial , immunology , genital herpes , virus , viral disease , herpesviridae , genetics , biology

Current therapy of herpes infections relies on nucleoside analogues. Pritelivir is a well-tolerated novel herpes simplex virus (HSV) helicase-primase inhibitor that reduced genital shedding and lesions.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research